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Usually, the onset of all types of cancers is
characterized by a genetic mutation leading to cell
proliferation, which further increases the probability of
genetic damage. Similar to genetic causes, external
stimuli is equally important for the initiation and
progression of cancers. If environmental factors such
as radiation and exposure to carcinogens are excluded
a potential candidate for cancer causation is chronic
inflammation (Balkwill, 2004). Chronic inflammation
accounts for 20% of all types of human cancers
(Coussens et. al., 2004). Population studies have
demonstrated the increase susceptibility of cells to be
come cancerous when exposed to chronic
inflammation. Although, a lot is known regarding the
pathological links between inflammation and cancer,
the signal transduction pathways underlying them is still
unresolved. The study by Pikarsky et. al., (2004)
explored this question. They proposed the nuclear
factor (NF-kB) to be a pivotal protein in the link between
inflammation and cancer. NF-kB characterizes all
inflammatory responses (Li et. al., 2002) and is also a
major hallmark of tumors (Lin et. al., 2003; Mayo,
2000).
In order to study this link they chose to use
Mrd2 knockout mice, which are characterized by
hepatocellular carcinoma (HCC; Nakamoto, 1998).
HCC progresses through distinct stages of
inflammation, dysplasia, carcinoma and metastasis,
thereby making it an ideal system for studying the
connection between inflammations and cancer (Block,
2003). When compared to control mice, Pikarsky et. al.,
(2004) noted high expression of NF-kB in HCC mice
demonstrating a potential link between NF- kB and
cancer. To further confirm the direct relationship
between NF-kB and the progression of cancer, they
treated HCC mice with anti-inflammatory drugs, which
resulted in the rescue of cells from becoming
cancerous. The study also showed that the expression
levels of NF- kB varied with the stage of the cancerous
cell thereby showing a regulatory mechanism for NF-kB
expression.
To investigate the regulatory mechanism that
controls NF-kB levels, Pikarsky et. al., (2004) chose the
tumor-necrosis-facor (TNF-alpha), since it is a common
pro-inflammatory mediator that is actively expressed by
neighboring cells that directly controls inflammatory
responses. Treating the HCC mice liver extracts with
anti-TNF-alpha antibodies that inhibited TNF-alpha
activity showed ablation of cancer progression and
decrease levels of MF-Kb. From the perspective of
tumorogenesis, NF- kB can thus be placed as one of
the several proteins that expedite the progression of
cancer. By definition, cancer refers to uncontrolled cell
division with the complete inhibition of apoptotic
mechanisms of normal cells. To test the possibility of
NF-kB inhibiting apoptosis, Pikarsky et al., (2004)
demonstrated increased apoptosis in cells treated with
anti-inflammatory drugs. This further confirms the
significant role of NF-kB in HCC progression.
Experimentally, Pikarsky et. al., clearly
demonstrates the link between NF-kB and cancer
through TNF-alpha. However, the study has not
answered the question of whether the anti-cancerous
properties of NF-kB and TNF-alpha is linked with its
roles in the signal transduction pathways underlying
inflammation. Since, they have not investigated the
cytokine expression with the changes in NF-kB and
TNF-alpha. It is important to investigate cytokine
expression because they are the workhorses of the
inflammatory system. Therefore, it possible for us to
propose a model where over expressed NF-kB and
TNF-alpha are acting as oncogenes through unknown
molecular pathways. However, most recent studies by
Greten et. al., (2004) that showed increased cytokine
and TNF-alpha in cancerous microenvironment
supports the model of Pikarsky et. al., (2004). From a
therapeutic viewpoint, the most crucial discovery by
Pikarsky’s group was the late effect of NF-kB in cancer
progression. They did not see any effect of NF-kB over
expression in the initial stages of tumorogeneisis.
However, NF-kB inactivation in the later stages led to
the suppression of tumor formation suggesting that
drugs targeting NF-kB can potentially act us good
therapies for cancers at late stages. The late effect of
NF-kB also indicates the complexity associated with
cancer progression. This further expands the field with
more novel questions such as the regulatory
mechanisms other than TNF-alpha for NF-kB.








Figure 1. Control of Cell Fate by NF-kB and TNF-alpha
During inflammatory responses, cytokines and several other unknown signals activate TNF-alpha. Once activated, TNF-alpha can induce
excessive cell proliferation and therefore cancer. Activation of TNF-alpha also activates NF-kB, which can further enhance the proression of
proliferating cells to tumors.
In the second part of Pikarsky’s study shows
the anti-apoptotic properties of NF-Kb and uses it as a
premise to propose the therapeutic potential of NF-kb.
However, we should also consider the impact of
inhibiting a major inflammatory protein such as NF-kb
or TNF-alpha for tumor suppression. Since, it may
affect the normal immuno and inflammatory responses
of our body. Thus, if either NF-kB or TNF-alpha is used
as a target for tumor suppressing drugs, the treatment
must be done in a way that does not affect the regular
homeostasis of the body. Although, Pikarsky’s study
demonstrates the halting of tumor progression by
inhibiting NF-kB or TNF-alpha, the study needs to be
repeated in other types of inflammatory cancers for
further exploring the potential of using them as targets
for cancer-drug development.
In brief, the study exposed the role of NF-kB
and TNF-alpha in maintaining the delicate balance
between cell proliferation and apoptosis (Figure. 1). The
study also reveals two novel targets—a) NF-kB and b)
TNF-alpha for developing cancer drugs. When
compared to other therapeutic targets of cancer, the
novelty is the unique ways in which two molecular
targets of the same signal transduction pathway (Figure
1) acts. Blocking TNF-alpha function will allow the
eradication of the primary causes of cancer. NF-kB
inhibition will help in halt tumor progression and
eliminates tumors thereby making it an ideal target for
drugs to be used at later stages of cancers.
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